Compare ABEO & FTF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ABEO | FTF |
|---|---|---|
| Founded | 1974 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 281.0M | 256.6M |
| IPO Year | 1980 | N/A |
| Metric | ABEO | FTF |
|---|---|---|
| Price | $5.05 | $6.11 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $18.20 | N/A |
| AVG Volume (30 Days) | ★ 2.8M | 153.9K |
| Earning Date | 11-12-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 11.45% |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.29 | N/A |
| Revenue | ★ $400,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $324.71 | N/A |
| P/E Ratio | $3.94 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.93 | $5.76 |
| 52 Week High | $7.54 | $6.56 |
| Indicator | ABEO | FTF |
|---|---|---|
| Relative Strength Index (RSI) | 56.25 | 48.07 |
| Support Level | $4.37 | $5.96 |
| Resistance Level | $5.17 | $6.17 |
| Average True Range (ATR) | 0.32 | 0.04 |
| MACD | 0.12 | 0.01 |
| Stochastic Oscillator | 65.80 | 70.73 |
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel.
Franklin Limited Duration Income Trust is a closed-end investment company based in the United States. It conducts its investment to provide high, current income, with a secondary objective of capital appreciation. To align with its investment objective is to invest in a diversified mix of fixed-income securities. Its portfolio is dominated by considerable investments in high-yield corporate bonds while touching upon other avenues such as senior secured floating rate corporate loans, mortgage-backed securities, commercial mortgage-backed securities, asset-backed securities, common stocks, and other short-term investments.